Clinical Advances in Hematology & Oncology最新文献

Advances in uterine serous carcinoma and uterine carcinosarcoma. 子宫浆液性癌和子宫癌肉瘤的研究进展。

IF 1.1

Clinical Advances in Hematology & Oncology Pub Date : 2025-05-01

Gini Fleming

引用次数: 0

The development of ATR inhibitors. ATR抑制剂的发展。

IF 1.1

Clinical Advances in Hematology & Oncology Pub Date : 2025-05-01

Timothy A Yap

引用次数: 0

Genetics of prostate cancer. 前列腺癌的遗传学。

IF 1.1

Clinical Advances in Hematology & Oncology Pub Date : 2025-05-01

Jeffrey W Shevach, Kathleen A Cooney

{"title":"Genetics of prostate cancer.","authors":"Jeffrey W Shevach, Kathleen A Cooney","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Prostate cancer is a highly heritable cancer, with contributions from rare pathogenic variants in prostate cancer predisposition genes (eg, HOXB13, BRCA2) and from common genetic variants throughout the genome. Only HOXB13 has been identified as a prostate cancer risk gene through linkage disequilibrium studies. Cancer predisposition genes in DNA damage repair pathways have been found to contribute to prostate cancer risk-particularly high-risk or metastatic prostate cancers-in family-based, clinic-based, and population-based studies. Polygenic and genomic risk scores based on common genetic variants identified in genome-wide association studies may have greater power to determine cancer risk than scores based on rare pathogenic variants, but the utility of these scores has yet to be rigorously studied prospectively. Individuals with high-risk or metastatic prostate cancers should be offered germline genetic testing to inform familial risk and screening practices, and to identify biomarker-based treatment options such as platinum-based chemotherapy or poly(ADP-ribose) polymerase inhibitors. Much work is needed to increase the use of germline genetic testing in individuals with prostate cancer, to improve equitable access to testing across all ethnic and racial groups, and to study the genomes of non-European ancestral populations in greater numbers to identify additional ancestry-specific risk variants.</p>","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":"23 3","pages":"144-152"},"PeriodicalIF":1.1,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144059857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Development of chimeric antigen receptor natural killer-cell therapy. 嵌合抗原受体自然杀伤细胞疗法的研究进展。

IF 1.1

Clinical Advances in Hematology & Oncology Pub Date : 2025-05-01

Katy Rezvani

引用次数: 0

Modern approaches in neuroendocrine tumors (NETs). 神经内分泌肿瘤（NETs）的现代方法。

IF 1.1

Clinical Advances in Hematology & Oncology Pub Date : 2025-05-01

Scott Paulson

引用次数: 0

Radiation therapy and MRI-based treatments in non-small cell lung cancer. 非小细胞肺癌的放射治疗和核磁共振治疗。